- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06108492
A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
December 27, 2023 updated by: Shanghai Hengrui Pharmaceutical Co., Ltd.
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-2005 for Intravesical perfusion in patients with high-risk non-muscle invasive bladder cancer.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
150
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Han Xu
- Phone Number: 0518-82342973
- Email: Han.xu@hengrui.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Zhongshan Hospital
-
Contact:
- Jianming Guo, Doctor
- Phone Number: +86-13681971306
- Email: Guo.jianming@zs-hospital.sh.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subjects must voluntarily agree to participate in the trial and sign a written informed consent form;
- ≥18 years of age, either sex;
- Previous pathological biopsy was diagnosed as high-risk NMIBC ;
- ECOG performance status of 0-1;
- Life expectancy ≥ 2 years;
- Adequate bone marrow and organ function.
Exclusion Criteria:
- Received TURBT or other surgical treatment or radiotherapy for bladder lesions within 2 weeks before the first administration;
- Patients who were receiving treatment in other clinical trials or less than 4 weeks from the end of the first administration in this study;
- History of serious cardiovascular and cerebrovascular diseases;
- Severe infection within 2 weeks prior to the first dose;
- Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per NCI-CTCAE v5.0;
- Oversize surgery or severe trauma within 4 weeks before the first use of research drugs;
- Previously received any TNFR agonist antibody therapy, such as OX40, CD137, CD27, CD357 antibodies.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SHR-2005
Only one arm with SHR-2005
|
In dose Escalation: Five dose levels are preset. The administration cycle included 6 times of induction perfusion period and 15 times of maintenance perfusion period. In indication Expansion: Indications will be selected to evaluate preliminary efficacy. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of dose limiting toxicities (DLTs)
Time Frame: From Day 1 to Day 21
|
From Day 1 to Day 21
|
Maximum tolerated dose (MTD)
Time Frame: From Day 1 to Day 21
|
From Day 1 to Day 21
|
Incidence and severity of adverse events (AEs) ([CTCAE] v5.0)
Time Frame: From Day 1 to 90 days after last dose
|
From Day 1 to 90 days after last dose
|
RP2D(Recommended Phase 2 dose)
Time Frame: From Day 1 to 90 days after last dose
|
From Day 1 to 90 days after last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response (DoR)
Time Frame: approximately within 36 months
|
Evaluated using RECIST 1.1
|
approximately within 36 months
|
Disease control rate (DCR)
Time Frame: approximately within 36 months
|
Evaluated using RECIST 1.1
|
approximately within 36 months
|
Progression-free survival (PFS)
Time Frame: approximately within 36 months
|
Evaluated using RECIST 1.1
|
approximately within 36 months
|
PK parameter: Tmax of SHR-2005
Time Frame: approximately 24 months
|
Time to maximum concentration of SHR-2005
|
approximately 24 months
|
PK parameter: Cmax of SHR-2005
Time Frame: approximately 24 months
|
Maximum concentration of SHR-2005
|
approximately 24 months
|
PK parameter: AUC0-∞ of SHR-2005
Time Frame: approximately 24 months
|
area under the concentration-time curve from time 0 to infinity of SHR-2005
|
approximately 24 months
|
Immunogenicity of SHR-2005
Time Frame: approximately 24 months
|
Anti- SHR-2005 antibody (ADA)
|
approximately 24 months
|
Amount_recovered and Percent_recovered
Time Frame: approximately 24 months
|
The Amount _ recovered and Percent _ recovered of SHR-2005 in urine after intravesical instillation.
|
approximately 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 28, 2023
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
September 30, 2027
Study Registration Dates
First Submitted
October 25, 2023
First Submitted That Met QC Criteria
October 25, 2023
First Posted (Actual)
October 31, 2023
Study Record Updates
Last Update Posted (Actual)
December 28, 2023
Last Update Submitted That Met QC Criteria
December 27, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Urinary Bladder Neoplasms
- Non-Muscle Invasive Bladder Neoplasms
Other Study ID Numbers
- SHR-2005-I-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High-risk Non-muscle Invasive Bladder Cancer
-
Archivel Farma S.L.Fundació Institut Germans Trias i PujolCompletedHigh-Risk Non-Muscle-Invasive Bladder CancerSpain
-
RemeGen Co., Ltd.Not yet recruitingHigh-risk Non-muscle Invasive Bladder CancerChina
-
University of Roma La SapienzaNot yet recruitingNon-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
-
Prokarium LtdRecruitingA Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer (PARADIGM-1)NMIBC | Non Muscle Invasive Bladder Cancer | High Risk NMIBCUnited States
-
Merck Sharp & Dohme LLCRecruitingHigh-risk Non-muscle Invasive Bladder CancerCanada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Norway, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Co... and more
-
University of British ColumbiaWithdrawnBladder Cancer | High-Risk Cancer | Durvalumab | Non-muscle Invasive | TremelimumabCanada
-
University of California, DavisNational Cancer Institute (NCI); IO BiotechRecruitingStage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
CG Oncology, Inc.RecruitingNon Muscle Invasive Bladder Cancer | High-grade Ta/ T1 Papillary Disease Bladder CancerUnited States, Korea, Republic of, Taiwan, Japan, Australia
-
Aura BiosciencesRecruitingMuscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder CancerUnited States
-
Nucleix Ltd.CompletedNon Muscle Invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
Clinical Trials on SHR-2005
-
University of GlasgowUnknownMaltreated InfantsUnited Kingdom
-
Region SkaneFolksam; Swedish Football Association; Swedish National Centre for Research in...Completed
-
Jiangsu HengRui Medicine Co., Ltd.CompletedAdvanced MalignanciesAustralia, China
-
Tianjin Medical University Cancer Institute and...Not yet recruitingEsophageal Squamous Cell Carcinoma | Progression to PD-1 AntibodyChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Non-small Cell Lung CancerChina
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Shanghai Hengrui Pharmaceutical Co., Ltd.RecruitingAlzheimer's DiseaseChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingAsthma With Eosinophilic PhenotypeChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedPrimary Hypercholesterolemia | Mixed HyperlipemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedPrimary HypercholesterolemiaChina